Biothera names chief medical officer
Biothera has named Patricia Molloy, M.D., chief medical officer. In this role, Molloy is responsible for the clinical development of Imprime PGG, the company’s immunotherapeutic oncology drug that is currently in multiple clinical trials for colorectal and lung cancer and chronic lymphocytic leukemia.
Molloy has more than 20 years of research experience with extensive late stage clinical development expertise in oncology, neurology and pediatrics. She was most recently vice president, global medical affairs and strategic consulting, for Premier Research Group.